Insights From Pharma 2025: Navigating The Evolution Of EU Health Technology Assessment (HTA) Regulation
The EU Health Technology Assessment (HTA) Regulation has become a reality, marking a new era for pharmaceutical market access across Europe. While the regulation promises streamlined assessments and faster patient access, its effective implementation is complex. At Pharma 2025, a discussion between Alexander Natz of EUCOPE and Herbert Altmann of Cencora explored these challenges and opportunities. Their conversation covered critical aspects such as giving smaller companies a voice, addressing resource constraints within HTA bodies, and creating a collaborative learning environment. Understanding these nuances is crucial for all stakeholders in the pharmaceutical ecosystem.
The discussion at Pharma 2025 highlighted the importance of a collaborative approach to implementing the EU HTA Regulation. By addressing the challenges and leveraging the opportunities, stakeholders can work towards achieving the regulation’s goals of improving patient access to new treatments.
As the pharmaceutical industry navigates this new regulatory landscape, it is essential to stay informed about the latest developments and insights. The conversation between Natz and Altmann provided valuable perspectives on the future of EU HTA and its potential impact on market access.
